The goal of the Behavioral Science Core (BSC) is to support the ERC-CFAR mission by facilitating the development and implementation of interdisciplinary, theory-driven, rigorous behavioral and social science research that aligns bench, bedside and community to prevent new HIV infections and improve HIV care. Behavioral and social science research continues to be indispensable to attenuating the HIV/AIDS epidemic, through ?combination prevention? which joins behavioral, social, and biomedical approaches; understanding acceptability, uptake, and adherence to effective biomedical technologies such as condoms, topical microbicides, intravaginal rings, PEP and PrEP, and emerging therapies such as bNAb; and reducing attrition at each stage of the HIV Prevention and Care continuum. The BSC has five Specific Aims: 1. Support development of new, innovative behavioral research by providing technical assistance on study design; qualitative and mixed methods through a new Qualitative Method Resource; and measurement. With the Clinical Translational Implementation Science Core (CTIS), we will assure translational potential. 2. Provide access to the Cognitive Interview Lab, a new resource staffed by trained interviewers who can test new measures and evaluate whether existing measures fit new populations or purposes. 3. Lead the ERC-CFAR Community Participatory Partnership to shape the ERC-CFAR research agenda. 4. With the Biomarker and Advanced Technology Core (BATC), guide combination measurement by developing new, and advising on existing, biomarkers for behavioral outcomes including ART and PrEP adherence from blood and hair drug anabolite assays, and RSID (a measure of semenogelin) in vaginal swabs and SPERM HI-LITER (immunofluorescence assay that detects sperm) for rectal swabs. 5. With the Development Core, mentor ESI, community and clinical researchers in behavioral research methods and community collaboration, and support collaboration through CFAR catalytic microgrants. The strengths of the BSC ? its foundation in existing expertise at Einstein and Hunter and its infrastructure (Qualitative Methods Resource, Cognitive Interview Lab, Biomarker advice, CPP) -- will provide essential support to enhance the capacity of the ERH-CFAR to meet its agenda, to arrest the AIDS epidemic.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Albert Einstein College of Medicine
United States
Zip Code
Bhalakia, Avni M; Talib, Hina J; Choi, Jaeun et al. (2018) Acceptance of Routine HIV Testing by Hospitalized Adolescents and Young Adults. Hosp Pediatr 8:187-193
Hannaford, Alisse; Lipshie-Williams, Madeleine; Starrels, Joanna L et al. (2018) The Use of Online Posts to Identify Barriers to and Facilitators of HIV Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men: A Comparison to a Systematic Review of the Peer-Reviewed Literature. AIDS Behav 22:1080-1095
Lu, Ching-Lan; Pai, Joy A; Nogueira, Lilian et al. (2018) Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption. Proc Natl Acad Sci U S A 115:E11341-E11348
Grov, Christian; Jonathan Rendina, H; Patel, Viraj V et al. (2018) Prevalence of and Factors Associated with the Use of HIV Serosorting and Other Biomedical Prevention Strategies Among Men Who Have Sex with Men in a US Nationwide Survey. AIDS Behav 22:2743-2755
Cohen, Yehuda Z; Lorenzi, Julio C C; Krassnig, Lisa et al. (2018) Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J Exp Med 215:2311-2324
Cohen, Yehuda Z; Lorenzi, Julio C C; Seaman, Michael S et al. (2018) Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. J Virol 92:
Cohen, Yehuda Z; Caskey, Marina (2018) Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection. Curr Opin HIV AIDS 13:366-373
Patel, Viraj V; Dange, Alpana; Rawat, Shruta et al. (2018) Barriers to HIV Testing Among Men Who Have Sex With Men in India Reached Online: Implications for Interventions. J Acquir Immune Defic Syndr 78:e30-e34
Liu, Yanyan; Ndumnego, Okechukwu C; Chen, Tingting et al. (2018) Soluble CD14 as a Diagnostic Biomarker for Smear-Negative HIV-Associated Tuberculosis. Pathogens 7:
Bar-On, Yotam; Gruell, Henning; Schoofs, Till et al. (2018) Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med 24:1701-1707

Showing the most recent 10 out of 27 publications